A. Brogan

发表

Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada

J. Mauskopf, Sarah A. Manuel, I. Adriaenssen, 2014, PharmacoEconomics.

Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States

A. Hill, J. Mrus, A. Brogan, 2010, HIV clinical trials.

Cost‐effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment‐naïve adults with HIV‐1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial

M. Fisher, E. Wilkins, S. Talbird, 2016, HIV medicine.

Cost-Effectiveness Analysis Of Tenofovir/Emtricitabine And Abacavir/Lamivudine In Combination With Efavirenz Or Atazanavir/Ritonavir For Treatment-Naive Adults With Hiv-1 Infection In The United Kingdom

M. Fisher, E. Wilkins, S. Talbird, 2014 .

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.

B. Sander, S. Talbird, A. Brogan, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA

J. Mauskopf, A. Brogan, E. Smets, 2012, PharmacoEconomics.

US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

J. Mauskopf, S. Talbird, A. Brogan, 2012, PharmacoEconomics.

The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States

S. Talbird, Princy N. Kumar, A. Brogan, 2021, PharmacoEconomics.

Creating Your Own Budget-Impact Analyses Today and Tomorrow

J. Mauskopf, S. Earnshaw, A. Brogan, 2017 .

COST ANALYSIS OF RALTEGRAVIR VERSUS ATAZANAVIR/R OR DARUNAVIR/R FOR TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION IN THE UNITED STATES

B. Goodwin, A. Brogan, A. Davis, 2016 .

Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK

A. Vyse, M. Slack, B. Hilton, 2018, Epidemiology and Infection.

Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection

J. Mauskopf, S. Talbird, A. Brogan, 2012, AIDS.

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

C. Cohen, S. Talbird, A. Brogan, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation.

R. Martindale, G. Cresci, A. Brogan, 2005, JPEN. Journal of parenteral and enteral nutrition.

Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.

S. Talbird, A. Brogan, A. Winiarski, 2009, American journal of preventive medicine.

Is increased screening and early antiretroviral treatment for HIV‐1 worth the investment? An analysis of the public health and economic impact of improvement in the UK

D. Flanagan, S. Talbird, A. Brogan, 2019, HIV medicine.

A note on separation in mean-lower-partial-moment portfolio optimization with fixed and moving targets

Shaler Stidham, Anita J. Brogan, S. Stidham, 2005 .

Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study.

D. Bisanzio, M. Gaudig, T. V. Van Effelterre, 2022, Vaccine.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

J. Javitt, Sonali N. Shah, A. Adamis, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C

Jeffrey D. Miller, S. Talbird, A. Brogan, 2014, PloS one.

Non-separation in the mean-lower-partial-moment portfolio optimization problem

Shaler Stidham, Anita J. Brogan, S. Stidham, 2008, Eur. J. Oper. Res..

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach

E. Thommes, G. Meier, S. Talbird, 2016, Human vaccines & immunotherapeutics.

IN3 Translating Outcomes from a Dynamic Transmission Model for Varicella Vaccination to Cost-Effectiveness Estimates: The Impact of Different Analytic Approaches on the Results

J. Mauskopf, B. Standaert, S. Talbird, 2012 .

Budget-Impact Analysis of Health Care Interventions: A Practical Guide

J. Mauskopf, T. Brodtkorb, S. Wolowacz, 2017 .

Budget-Impact Analysis of Health Care Interventions

J. Mauskopf, T. Brodtkorb, S. Earnshaw, 2017, Springer International Publishing.

Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection

J. Mauskopf, S. Talbird, A. Brogan, 2012, AIDS.

PEY11 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING EARLY AND LATE MACUGEN TREATMENT

Sonali N. Shah, A. Adamis, G. Zlateva, 2005 .

PEY9 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING MACUGEN TO VISUDYNE

Sonali N. Shah, A. Adamis, G. Zlateva, 2005 .

[Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].

A. Brogan, E. Smets, A. Sawyer, 2013, Enfermedades infecciosas y microbiologia clinica.

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.

B. Sander, S. Talbird, A. Brogan, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.